Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Cariprazine is not approved for the treatment of patients with dementia-related psychosis.
Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and for the emergence of suicidal thoughts and behaviors. The safety and efficacy of cariprazine have not been established in pediatric patients.
Dosage guidance:
Safety: Antipsychotics are not indicated for use in catatonia and may worsen psychosis and increase risk for neuroleptic malignant syndrome in patients with catatonia (Ref).
Clinical considerations: Consult a psychiatry specialist for all management decisions; select antipsychotic carefully based on patient preference, clinical characteristics, history, comorbidities, and adverse effect profile (Ref).
Bipolar disorder:
Acute mania and acute episodes with mixed features (monotherapy): Oral: Initial: 1.5 mg once daily; adjust dose based on response and tolerability to 3 mg on day 2 and make further adjustments in increments of 1.5 or 3 mg. Recommended dosing range: 3 mg to 6 mg once daily. Maximum dose: 6 mg/day (product labeling); doses up to 12 mg/day have been evaluated in clinical trials, however, greater efficacy has not been demonstrated (Ref).
Bipolar major depression (monotherapy): Oral: Initial: 1.5 mg once daily; increase based on response and tolerability to 3 mg on day 15. Maximum dose: 3 mg/day (Ref).
Major depressive disorder (unipolar) (adjunctive therapy with antidepressant): Oral: Initial: 1.5 mg once daily, may increase based on response and tolerability to 3 mg once daily on day 15. Maximum dose: 3 mg/day, however, some experts recommend increasing to 4.5 mg/day based on response and tolerability (Ref).
Schizophrenia:
Oral: Initial: 1.5 mg once daily; may adjust dose based on response and tolerability to 3 mg once daily on days 2 or 3. Starting as early as day 4, may further increase to 4.5 or 6 mg once daily based on response and tolerability. Monitor for akathisia, anticholinergic effects, and sedation during titration. Maximum dose: 6 mg/day (Ref).
Discontinuation of therapy: In the treatment of chronic psychiatric disease, switching therapy rather than discontinuation is generally advised if side effects are intolerable or treatment is not effective. If patient insists on stopping treatment, gradual dose reduction (ie, over several weeks to months) is advised to detect a re-emergence of symptoms and to avoid withdrawal reactions (eg, agitation, alternating feelings of warmth and chill, anxiety, diaphoresis, dyskinesias, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, vertigo) unless discontinuation is due to significant adverse effects. Monitor closely to allow for detection of prodromal symptoms of disease recurrence (Ref).
Switching antipsychotics: An optimal universal strategy for switching antipsychotic drugs has not been established. Strategies include: cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic) and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). In patients with schizophrenia at high risk of relapse, the current medication may be maintained at full dose as the new medication is increased (ie, overlap); once the new medication is at therapeutic dose, the first medication is gradually decreased and discontinued over 1 to 2 weeks (Ref).
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
CrCl ≥30 mL/minute: No dosage adjustment necessary.
CrCl <30 mL/minute: Use not recommended (has not been studied).
Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.
Severe impairment (Child-Pugh class C): Use not recommended (has not been studied).
Note: Avoid for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. If used, consider deprescribing attempts to assess continued need and/or lowest effective dose. Of note, use in certain indications (eg, adjunctive treatment of unipolar major depressive disorder, schizophrenia, bipolar disorder) may be appropriate (Ref). Consult a psychiatry specialist for all management decisions (Ref).
All indications: Refer to adult dosing; dosages in the lower range of recommended adult dosing are generally sufficient. Titrate dosage slowly and monitor carefully.
Both activating effects (eg, akathisia, restlessness) and sedating effects (eg, drowsiness, somnolence) may occur with cariprazine. In clinical studies, most instances of akathisia were considered mild or moderate, though events leading to treatment discontinuation were rarely reported (Ref). The mean duration of akathisia/restlessness in clinical studies was reported between 15 and 24 days (Ref).
Mechanism: Dose-related; sedation from antipsychotics is believed to be due to H1 receptor antagonism; mechanism of activating effects is not clear but is thought to involve GABA and serotonin effects on dopamine signaling (Ref)
Onset: Varied; in clinical studies, akathisia/restlessness most commonly occurred within the first 2 to 6 weeks of therapy (Ref)
Risk factors:
• Akathisia, restlessness: High doses, rapid up-titration (Ref)
• Somnolence: Doses ≥4.5 mg/day (Ref)
• Specific antipsychotic (cariprazine is generally considered to be minimally sedating at usual therapeutic doses in comparison with other antipsychotics) (Ref)
Cariprazine may cause an extrapyramidal reaction, also known as drug-induced movement disorders. Antipsychotics can cause four main extrapyramidal symptoms (EPS): drug-induced parkinsonism, akathisia, acute dystonia, and tardive dyskinesia. EPS presenting as dysphagia, esophageal dysmotility, or aspiration have also been reported with antipsychotics, which may not be recognized as EPS (Ref). In clinical studies, the mean duration of EPS for cases that resolved during study period was ~10 days (Ref).
Mechanism: Dose-related; due to antagonism of dopaminergic D2 receptors in nigrostriatal pathways (cariprazine is a partial agonist) (Ref)
Onset: Intermediate; in clinical studies, acute EPS occurred within the first 3 weeks of therapy (Ref).
Risk factors:
EPS (in general):
• Higher doses (Ref)
• Prior history of EPS (Ref)
Acute dystonia:
• Males (Ref)
• Young age (Ref)
Akathisia:
• Rapid up-titration (Ref)
• Mood disorders (Ref)
• Females (Ref)
• Older patients (Ref)
Drug-induced parkinsonism:
• Higher doses (Ref)
• Older patients (Ref)
• Females (Ref)
• Dementia (Ref)
Tardive dyskinesia:
• Greater total antipsychotic exposure (especially first-generation antipsychotics) (Ref)
• Concomitant treatment with anticholinergic medications (Ref)
• Substance misuse or dependence (Ref)
• Age >55 years (Ref)
• Cognitive impairment (Ref)
• Diabetes (Ref)
• Diagnosis of schizophrenia or affective disorders (Ref)
• Females (Ref)
• History of extrapyramidal symptoms (Ref)
Esophageal dysfunction (associated with EPS):
• Certain comorbidities such as neurologic degenerative disease, dementia, stroke, Parkinson disease, or myasthenia gravis (Ref)
• Older adults >75 years of age (may be risk factor due to age-related muscle atrophy, cognitive impairment, reduced esophageal peristalsis) (Ref)
Leukopenia and neutropenia have been reported with cariprazine. Agranulocytosis has been reported with other second-generation antipsychotics.
Onset: Varied; in general, drug-induced neutropenia usually manifests after 1 or 2 weeks of exposure; however, the onset may be insidious (Ref)
Risk factors:
• Preexisting low white blood cell count or absolute neutrophil count
• History of drug-induced leukopenia or neutropenia
Antipsychotics are associated with hyperglycemia to varying degrees, which is a component of the metabolic syndrome, observed with this pharmacologic class. Cariprazine is associated with a low risk of metabolic alterations; however, increased A1c and blood glucose have been reported with long-term use (Ref).
Mechanism: Mechanism is not entirely understood (Ref)
Risk factors:
Antipsychotics in general:
• African American race (Ref)
• Males (Ref)
• Age <35 years (Ref)
• Preexisting obesity, poor exercise habits, or other risk factors for diabetes, including family history of diabetes (Ref)
• Exposure to other agents that also increase the risk of hyperglycemia (Ref)
• Specific antipsychotic: Metabolic disturbances appear to be the greatest with clozapine and olanzapine and lower with cariprazine (Ref)
Antipsychotics are associated with neuroleptic malignant syndrome (NMS), although the incidence is lower with second-generation (atypical) antipsychotics compared to first-generation (typical) antipsychotics. There is one published case report of NMS with cariprazine (in combination with other psychiatric medications) (Ref).
Mechanism: Non–dose-related; idiosyncratic. Believed to be due to a reduction in CNS dopaminergic tone, along with the dysregulation of autonomic nervous system activity (Ref)
Onset: Varied; in general, most patients develop NMS within 2 weeks of initiating an antipsychotic, and in some patients, prodromal symptoms emerge within hours of initiation; once the syndrome starts, the full syndrome usually develops in 3 to 5 days (Ref). However, there are many cases of NMS occurring months after stable antipsychotic therapy (Ref)
Risk factors:
Antipsychotics in general:
• Males (twice as likely to develop NMS compared to females) (Ref)
• Dehydration (Ref)
• High-dose antipsychotic treatment (Ref)
• Concomitant lithium or benzodiazepine (potential risk factors) (Ref)
• Catatonia (Ref)
• Polypharmacy (Ref)
• Pharmacokinetic interactions (Ref)
• Intramuscular administration (Ref)
• Rapid dosage escalation (Ref)
• Psychomotor agitation (Ref)
Antipsychotics may impair the body's ability to regulate core body temperature, which may cause a potentially life-threatening heat stroke during predisposing conditions, such as heat wave or strenuous exercise.
Risk factors:
Heat stroke (antipsychotics in general):
• Psychiatric illness (regardless of medication use) (Ref)
• Dehydration (Ref)
• Strenuous exercise (Ref)
• Heat exposure (Ref)
• Concomitant medications possessing anticholinergic effects (Ref)
Cariprazine may cause significant weight gain (increase of ≥7% from baseline), which is a component of the metabolic syndrome observed with this pharmacologic class.
Mechanism: Multiple proposed mechanisms, including actions at serotonin, dopamine, histamine, and muscarinic receptors, with differing effects explained by differing affinity of antipsychotics at these receptors (Ref). A low affinity for serotonin and histamine receptors may account for the relatively low risk of weight gain associated with cariprazine (Ref).
Onset: Varied; antipsychotic-induced weight gain usually occurs rapidly in the initial period following initiation, then gradually plateaus over several months with patients continuing to gain weight in the long term (Ref).
Risk factors:
Antipsychotics in general:
• Family history of obesity (Ref)
• Parental BMI (Ref)
• Rapid weight gain in the initial period: Younger age, lower baseline BMI, more robust response to antipsychotic, and increase in appetite; rapid weight gain of >5% in the first month has been observed as the best predictor for significant long-term weight gain (Ref)
• Duration of therapy (although weight gain plateaus, patients continue to gain weight over time) (Ref)
• Schizophrenia (regardless of medication) is associated with a higher prevalence of obesity compared to the general population due to components of the illness, such as negative symptoms, sedentary lifestyles, and unhealthy diets (Ref)
• Specific antipsychotic: Cariprazine is considered to have a minimal or low risk for weight gain; clozapine and olanzapine are considered to have high propensity (Ref)
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported for monotherapy in adults.
>10%:
Gastrointestinal: Nausea (7% to 13%)
Nervous system: Akathisia (6% to 20%) (table 1) , extrapyramidal reaction (4% to 26%; including dyskinesia, dystonia, muscle rigidity, Parkinsonism, tardive dyskinesia) (table 2) , headache (14%), insomnia (9% to 13%)
Drug (Cariprazine) |
Placebo |
Dose |
Indication |
Number of Patients (Cariprazine) |
Number of Patients (Placebo) |
---|---|---|---|---|---|
10% |
2% |
3 mg/day |
Bipolar disorder, depressive episode |
469 |
468 |
6% |
2% |
1.5 mg/day |
Bipolar disorder, depressive episode |
470 |
468 |
20% |
5% |
3 to 6 mg/day |
Bipolar mania |
263 |
442 |
13% |
4% |
4.5 to 6 mg/day |
Schizophrenia |
575 |
584 |
9% |
4% |
1.5 to 3 mg/day |
Schizophrenia |
539 |
584 |
Drug (Cariprazine) |
Placebo |
Dose |
Indication |
Number of Patients (Cariprazine) |
Number of Patients (Placebo) |
---|---|---|---|---|---|
6% |
2% |
3 mg/day |
Bipolar disorder, depressive episode |
469 |
468 |
4% |
2% |
1.5 mg/day |
Bipolar disorder, depressive episode |
470 |
468 |
26% |
12% |
3 to 6 mg/day |
Bipolar mania |
263 |
442 |
19% |
8% |
4.5 to 6 mg/day |
Schizophrenia |
575 |
584 |
15% |
8% |
1.5 to 3 mg/day |
Schizophrenia |
539 |
584 |
1% to 10%:
Cardiovascular: Hypertension (2% to 5%), tachycardia (2%)
Endocrine & metabolic: Weight gain (1% to 8%) (table 3)
Drug (Cariprazine) |
Placebo |
Dose |
Indication |
Number of Patients (Cariprazine) |
Number of Patients (Placebo) |
Comments |
---|---|---|---|---|---|---|
3% |
1% |
1.5 mg/day |
Bipolar disorder, depressive episode |
467 |
463 |
Patients with weight increase ≥7% |
3% |
1% |
3 mg/day |
Bipolar disorder, depressive episode |
465 |
463 |
Patients with weight increase ≥7% |
2% |
<1% |
1.5 mg/day |
Bipolar disorder, depressive episode |
470 |
468 |
N/A |
2% |
<1% |
3 mg/day |
Bipolar disorder, depressive episode |
469 |
468 |
N/A |
2% |
2% |
3 to 6 mg/day |
Bipolar mania |
263 |
442 |
N/A |
1% |
2% |
3 to 6 mg/day |
Bipolar mania |
259 |
439 |
Patients with weight increase ≥7% |
8% |
5% |
1.5 to 3 mg/day |
Schizophrenia |
512 |
573 |
Patients with weight increase ≥7% |
8% |
5% |
4.5 to 6 mg/day |
Schizophrenia |
570 |
573 |
Patients with weight increase ≥7% |
3% |
1% |
1.5 to 3 mg/day |
Schizophrenia |
539 |
584 |
N/A |
2% |
1% |
4.5 to 6 mg/day |
Schizophrenia |
575 |
584 |
N/A |
Gastrointestinal: Abdominal pain (6%), constipation (6% to 7%), decreased appetite (3%), diarrhea (4%), dyspepsia (5% to 7%), increased appetite (3%), toothache (4%), vomiting (4% to 10%), xerostomia (3%)
Hepatic: Increased serum transaminases (≥3 x ULN; 2% to 4%)
Nervous system: Agitation (5%), anxiety (5% to 6%), dizziness (3% to 7%), drowsiness (5% to 8%) (table 4) , fatigue (3% to 4%), restlessness (2% to 7%) (table 5)
Drug (Cariprazine) |
Placebo |
Dose |
Indication |
Number of Patients (Cariprazine) |
Number of Patients (Placebo) |
---|---|---|---|---|---|
7% |
4% |
1.5 mg/day |
Bipolar disorder, depressive episode |
470 |
468 |
6% |
4% |
3 mg/day |
Bipolar disorder, depressive episode |
469 |
468 |
7% |
4% |
3 to 6 mg/day |
Bipolar mania |
263 |
442 |
8% |
5% |
4.5 to 6 mg/day |
Schizophrenia |
575 |
584 |
5% |
5% |
1.5 to 3 mg/day |
Schizophrenia |
539 |
584 |
Drug (Cariprazine) |
Placebo |
Dose |
Indication |
Number of Patients (Cariprazine) |
Number of Patients (Placebo) |
---|---|---|---|---|---|
7% |
3% |
3 mg/day |
Bipolar disorder, depressive episode |
469 |
468 |
2% |
3% |
1.5 mg/day |
Bipolar disorder, depressive episode |
470 |
468 |
7% |
2% |
3 to 6 mg/day |
Bipolar mania |
263 |
442 |
6% |
3% |
4.5 to 6 mg/day |
Schizophrenia |
575 |
584 |
4% |
3% |
1.5 to 3 mg/day |
Schizophrenia |
539 |
584 |
Neuromuscular & skeletal: Arthralgia (2%), back pain (3%), increased creatine phosphokinase in blood specimen (2% to 6%), limb pain (4%)
Ophthalmic: Blurred vision (4%)
<1%:
Dermatologic: Hyperhidrosis
Endocrine & metabolic: Hyponatremia
Gastrointestinal: Gastritis, gastroesophageal reflux disease
Genitourinary: Pollakiuria
Hepatic: Hepatitis
Nervous system: Cerebrovascular accident, suicidal ideation, suicidal tendencies
Neuromuscular & skeletal: Rhabdomyolysis
Frequency not defined:
Endocrine & metabolic: Diabetes mellitus, dyslipidemia, hyperglycemia
Ophthalmic: Cataract
Postmarketing:
Dermatologic: Stevens-Johnson syndrome
Endocrine & metabolic: Hyperprolactinemia (Ref)
Gastrointestinal: Dysphagia
Hematologic & oncologic: Leukopenia, neutropenia
Hypersensitivity (rash, pruritus, urticaria, angioedema) to cariprazine or any component of the formulation.
Canadian labeling: Additional contraindications (not in US labeling): Coadministration with or within 2 weeks of moderate and strong CYP3A4 inhibitors; coadministration with moderate and strong CYP3A4 inducers.
Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
Concerns related to adverse effects:
• Falls: May increase the risk for falls due to somnolence, orthostatic hypotension, and motor or sensory instability.
• Orthostatic hypotension: May cause orthostatic hypotension; risk is increased at initial dose titration and when increasing the dose. Use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (patients who are antipsychotic-naive or have cerebrovascular disease, cardiovascular disease, hypovolemia, dehydration, or are taking concurrent medication use which may predispose to hypotension/bradycardia).
Disease-related concerns:
• Dementia: [US Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo. Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Use with caution in patients with Lewy body dementia or Parkinson disease dementia due to greater risk of adverse effects, increased sensitivity to extrapyramidal effects, and association with irreversible cognitive decompensation or death (APA [Reus 2016]). Cariprazine is not approved for the treatment of dementia-related psychosis.
• Hepatic impairment: Use with caution in patients with hepatic impairment; use is not recommended in severe impairment.
• Renal impairment: Use with caution in patients with renal impairment; use is not recommended if CrCl <30 mL/minute.
• Seizures: Use with caution in patients at risk of seizures or with conditions that potentially lower the seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predisposing factors.
Other warnings/precautions:
• Discontinuation of therapy: When discontinuing antipsychotic therapy, gradually taper antipsychotics to avoid physical withdrawal symptoms and rebound symptoms (APA [Keepers 2020]; WFSBP [Hasan 2012]). Withdrawal symptoms may include agitation, alternating feelings of warmth and cold, anxiety, diaphoresis, dyskinesia, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, and vertigo (Lambert 2007; Moncrieff 2020). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anticholinergic or dopaminergic antipsychotics (Cerovecki 2013). Patients with chronic symptoms, repeated relapses, and clear diagnostic features of schizophrenia are at risk for poor outcomes if medications are discontinued (APA [Keepers 2020]).
• Pharmacokinetics: Plasma levels of cariprazine and its major metabolites accumulate over time. Adverse reactions may not appear until several weeks after initiation of treatment. Monitor response and for adverse reactions several weeks after the patient has begun treatment and after each dose increase. With treatment discontinuation the plasma concentration of cariprazine and active metabolites declines by 50% in ~1 week; therefore, the decline of plasma concentrations of active drug and metabolite may not be immediately reflected in the patient's clinical symptoms.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Capsule, Oral:
Vraylar: 1.5 mg
Vraylar: 3 mg, 4.5 mg [contains fd&c blue #1 (brilliant blue), fd&c red #40 (allura red ac dye)]
Vraylar: 6 mg [contains fd&c blue #1 (brilliant blue)]
Capsule Therapy Pack, Oral:
Vraylar: 1.5 mg (1) and 3 mg (6s) (7 ea [DSC]) [contains fd&c blue #1 (brilliant blue), fd&c red #40 (allura red ac dye)]
No
Capsules (Vraylar Oral)
1.5 mg (per each): $60.76
3 mg (per each): $60.76
4.5 mg (per each): $60.76
6 mg (per each): $60.76
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Capsule, Oral:
Vraylar: 1.5 mg
Vraylar: 3 mg, 4.5 mg [contains fd&c blue #1 (brilliant blue), fd&c red #40 (allura red ac dye)]
Vraylar: 6 mg [contains fd&c blue #1 (brilliant blue), fd&c red #3 (erythrosine sodium)]
Oral: Administer with or without food.
An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:
Vraylar: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/204370s012lbl.pdf#page=46
Bipolar disorder: Acute treatment of mania or episodes with mixed features and major depression associated with bipolar I disorder.
Major depressive disorder (unipolar): Adjunctive therapy in adults with an inadequate response to antidepressants for the treatment of unipolar major depressive disorder.
Schizophrenia: Treatment of schizophrenia.
Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older due to an increased risk of stroke and a greater rate of cognitive decline and mortality in patients with dementia. Evidence also suggests there may be an increased risk of mortality with use independent of dementia. Avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. Use of antipsychotics may be appropriate for labeled indications including schizophrenia, bipolar disorder, Parkinson disease psychosis, adjunctive therapy in major depressive disorder, or for short-term use as an antiemetic (Beers Criteria [AGS 2023]).
Substrate of CYP2D6 (Minor), CYP3A4 (Major with inhibitors), CYP3A4 (Minor with inducers); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.
Agents With Seizure Threshold Lowering Potential: May increase adverse/toxic effects of Cariprazine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Amifampridine: Agents With Seizure Threshold Lowering Potential may increase neuroexcitatory and/or seizure-potentiating effects of Amifampridine. Risk C: Monitor
Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Amisulpride (Oral). Specifically, the risk of seizures may be increased. Risk C: Monitor
Amisulpride (Oral): May increase adverse/toxic effects of Antipsychotic Agents. Specifically, the risk of neuroleptic malignant syndrome or increased QTc interval may be increased. Risk C: Monitor
Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (Second Generation [Atypical]) may decrease therapeutic effects of Anti-Parkinson Agents (Dopamine Agonist). Management: Consider avoiding atypical antipsychotic use in patients with Parkinson disease. If an atypical antipsychotic is necessary, consider using clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin). Risk D: Consider Therapy Modification
Antidiabetic Agents: Hyperglycemia-Associated Agents may decrease therapeutic effects of Antidiabetic Agents. Risk C: Monitor
ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. Risk C: Monitor
ARIPiprazole: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of ARIPiprazole. Specifically, the risk of seizures may be increased. Risk C: Monitor
Asenapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Asenapine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Benperidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Benperidol. Specifically, the risk of seizures may be increased. Risk C: Monitor
Benzgalantamine-Galantamine: May increase neurotoxic (central) effects of Antipsychotic Agents. Risk C: Monitor
Blonanserin: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Blonanserin. Specifically, the risk of seizures may be increased. Risk C: Monitor
Blood Pressure Lowering Agents: May increase hypotensive effects of Antipsychotic Agents (Second Generation [Atypical]). Risk C: Monitor
Bornaprine: May increase adverse/toxic effects of Antipsychotic Agents. Specifically, tardive dyskinesia symptoms may be potentiated. Risk C: Monitor
Brexpiprazole: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Brexpiprazole. Specifically, the risk of seizures may be increased. Risk C: Monitor
Bromopride: May increase adverse/toxic effects of Antipsychotic Agents. Risk X: Avoid
Bromperidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Bromperidol. Specifically, the risk of seizures may be increased. Risk C: Monitor
BuPROPion: May increase neuroexcitatory and/or seizure-potentiating effects of Agents With Seizure Threshold Lowering Potential. Risk C: Monitor
Cabergoline: May decrease therapeutic effects of Antipsychotic Agents. Risk X: Avoid
ChlorproMAZINE: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of ChlorproMAZINE. Specifically, the risk of seizures may be increased. Risk C: Monitor
Clofazimine: May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor
Clothiapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Clothiapine. Specifically, the risk of seizures may be increased. Risk C: Monitor
CloZAPine: Cariprazine may increase adverse/toxic effects of CloZAPine. Specifically, the risk of seizures may be increased. Cariprazine may decrease serum concentration of CloZAPine. Cariprazine may decrease active metabolite exposure of CloZAPine. Risk C: Monitor
CYP3A4 Inducers (Moderate): May decrease serum concentration of Cariprazine. Risk X: Avoid
CYP3A4 Inducers (Strong): May decrease serum concentration of Cariprazine. Risk X: Avoid
CYP3A4 Inhibitors (Moderate): May increase serum concentration of Cariprazine. CYP3A4 Inhibitors (Moderate) may increase active metabolite exposure of Cariprazine. Management: Cariprazine dose adjustments are recommended and depend upon whether a patient is initiating a moderate CYP3A4 inhibitor or cariprazine, as well as cariprazine indication. See full mono for details. Some non-US labels contraindicate this combination. Risk D: Consider Therapy Modification
CYP3A4 Inhibitors (Strong): May increase serum concentration of Cariprazine. CYP3A4 Inhibitors (Strong) may increase active metabolite exposure of Cariprazine. Specifically, concentrations of didesmethylcariprazine (DDCAR), the primary active metabolite of cariprazine, may increase. Management: Cariprazine dose adjustments are recommended and depend upon whether a patient is initiating a strong CYP3A4 inhibitor or cariprazine, as well as cariprazine indication. See full mono for details. Some non-US labels contraindicate this combination. Risk D: Consider Therapy Modification
Deutetrabenazine: May increase adverse/toxic effects of Antipsychotic Agents. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased. Risk C: Monitor
Dexmethylphenidate-Methylphenidate: Antipsychotic Agents may increase adverse/toxic effects of Dexmethylphenidate-Methylphenidate. Dexmethylphenidate-Methylphenidate may increase adverse/toxic effects of Antipsychotic Agents. Specifically, the risk of extrapyramidal symptoms may be increased when these agents are combined. Risk C: Monitor
Donepezil: May increase neurotoxic (central) effects of Antipsychotic Agents. Risk C: Monitor
DroPERidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of DroPERidol. Specifically, the risk of seizures may be increased. Risk C: Monitor
Flupentixol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Flupentixol. Specifically, the risk of seizures may be increased. Risk C: Monitor
FluPHENAZine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of FluPHENAZine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Fusidic Acid (Systemic): May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Consider avoiding this combination if possible. If required, monitor patients closely for increased adverse effects of the CYP3A4 substrate. Risk D: Consider Therapy Modification
Grapefruit Juice: May increase serum concentration of Cariprazine. Management: Advise patients taking cariprazine to avoid consumption of grapefruit juice. Because grapefruit juice consumption is highly variable, typical dose adjustments associated with moderate CYP3A4 inhibitors are not likely feasible. Risk D: Consider Therapy Modification
Guanethidine: Antipsychotic Agents may decrease therapeutic effects of Guanethidine. Risk C: Monitor
Haloperidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Haloperidol. Specifically, the risk of seizures may be increased. Risk C: Monitor
Huperzine A: May increase neurotoxic (central) effects of Antipsychotic Agents. Risk C: Monitor
Iloperidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iloperidone. Specifically, the risk of seizures may be increased. Risk C: Monitor
Iohexol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider Therapy Modification
Iomeprol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider Therapy Modification
Iopamidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider Therapy Modification
Lithium: May increase neurotoxic effects of Antipsychotic Agents. Lithium may decrease serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine. Risk C: Monitor
Loxapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Loxapine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Lumateperone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Lumateperone. Specifically, the risk of seizures may be increased. Risk C: Monitor
Lurasidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Lurasidone. Specifically, the risk of seizures may be increased. Risk C: Monitor
Metergoline: Antipsychotic Agents may decrease therapeutic effects of Metergoline. Metergoline may decrease therapeutic effects of Antipsychotic Agents. Risk C: Monitor
Methotrimeprazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Methotrimeprazine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Metoclopramide: May increase adverse/toxic effects of Antipsychotic Agents. Risk X: Avoid
MetyroSINE: May increase adverse/toxic effects of Antipsychotic Agents. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased. Risk C: Monitor
Molindone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Molindone. Specifically, the risk of seizures may be increased. Risk C: Monitor
OLANZapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of OLANZapine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Paliperidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Paliperidone. Specifically, the risk of seizures may be increased. Risk C: Monitor
Periciazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Periciazine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Perphenazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Perphenazine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Pimozide: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Pimozide. Specifically, the risk of seizures may be increased. Risk C: Monitor
Pipamperone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Pipamperone. Specifically, the risk of seizures may be increased. Risk X: Avoid
Piribedil: Antipsychotic Agents may decrease therapeutic effects of Piribedil. Piribedil may decrease therapeutic effects of Antipsychotic Agents. Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended. Risk X: Avoid
Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. Risk C: Monitor
Prochlorperazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Prochlorperazine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Promazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Promazine. Specifically, the risk of seizures may be increased. Risk C: Monitor
QUEtiapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of QUEtiapine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Quinagolide: Antipsychotic Agents may decrease therapeutic effects of Quinagolide. Risk C: Monitor
RisperiDONE: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of RisperiDONE. Specifically, the risk of seizures may be increased. Risk C: Monitor
Rivastigmine: May increase neurotoxic (central) effects of Antipsychotic Agents. Risk C: Monitor
Serotonergic Agents (High Risk): May increase adverse/toxic effects of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Risk C: Monitor
Sertindole: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Sertindole. Specifically, the risk of seizures may be increased. Risk C: Monitor
Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. Risk C: Monitor
Sulpiride: Antipsychotic Agents may increase adverse/toxic effects of Sulpiride. Risk X: Avoid
Tetrabenazine: May increase adverse/toxic effects of Antipsychotic Agents. Specifically, the risk for NMS and extrapyramidal symptoms may be increased. Risk C: Monitor
Thioridazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Thioridazine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Thiothixene: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Thiothixene. Specifically, the risk of seizures may be increased. Risk C: Monitor
Trifluoperazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Trifluoperazine. Specifically, the risk of seizures may be increased. Risk C: Monitor
Ziprasidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Ziprasidone. Specifically, the risk of seizures may be increased. Risk C: Monitor
Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Zuclopenthixol. Specifically, the risk of seizures may be increased. Risk C: Monitor
Evaluate pregnancy status and provide preconception counseling prior to initiating treatment in patients who could become pregnant (APA [Keepers 2020]; BAP [McAllister-Williams 2017]; CANMAT [Yatham 2018]). Patients effectively treated may continue their current antipsychotic medication when planning a pregnancy unless contraindications exist (ACOG 2023; BAP [McAllister-Williams 2017]); the lowest effective dose and avoidance of polytherapy is recommended (BAP [Barnes 2020]; BAP [McAllister-Williams 2017]; CANMAT [Yatham 2018]). Management of mental health conditions in patients who could become pregnant should be based on a shared decision-making process that considers the possibility of pregnancy during treatment and the risks of discontinuing antipsychotic therapy (ACOG 2023; BAP [McAllister-Williams 2017]; CANMAT [Yatham 2018]).
Antipsychotic agents may be associated with sexual dysfunction. Some second generation (atypical) antipsychotics may cause hyperprolactinemia, resulting in menstrual disorders or impaired spermatogenesis. Consider changing to a medication that is prolactin-sparing in patients with clinical symptoms. Contraception should be provided if pregnancy is not desired, as unintended pregnancies may occur when changing to a prolactin-sparing medication (APA [Keepers 2020]; BAP [McAllister-Williams 2017]).
Outcome data following exposure to second generation (atypical) antipsychotics (SGAs) as a class do not show a significant increased risk of major congenital malformations (BAP [Barnes 2020]); however, specific outcomes vary due to differences in study design and data are not specific for cariprazine (BAP [McAllister-Williams 2017]; Viguera 2021; Wang 2021). Additional studies are needed for individual agents and specific outcomes (BAP [Barnes 2020]). Data related to the long-term effects of in utero antipsychotic exposure on infant neurodevelopment and behavior are limited (BAP [McAllister-Williams 2017]; Straub 2022; Swetlik 2024).
Antipsychotic use during the third trimester of pregnancy increases the risk for extrapyramidal symptoms and/or withdrawal symptoms in newborns following delivery (Viguera 2023). Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor. These effects may require prolonged hospitalization or resolve within hours or days without specific treatment. Tapering the dose late in pregnancy to reduce the risk of symptoms is not recommended (APA [Keepers 2020]).
Atypical antipsychotics are associated with metabolic changes and the risk varies by specific agent. Available studies that evaluated the risk of developing gestational diabetes mellitus (GDM) during antipsychotic therapy have conflicting results, possibly due to differences in study design (ACOG 2023; Uguz 2019). Pregnant patients with diabetes mellitus or GDM may continue antipsychotic treatment (ACOG 2023). Consider the metabolic risks of the specific antipsychotic if treatment is initiated for the first time during pregnancy (Heinonen 2022). Screening for GDM should continue as part of standard prenatal care; early screening is not needed due to psychiatric medication exposure (ACOG 2023; BAP [McAllister-Williams 2017]).
Untreated and undertreated mental health conditions are associated with adverse pregnancy outcomes (ACOG 2023). Adverse obstetric and neonatal outcomes are associated with schizophrenia; however, comparisons between treated and untreated pregnancies are limited (BAP [McAllister-Williams 2017]). Untreated or undertreated depression is associated with preterm birth, low birth weight, preeclampsia, postpartum depression, and impaired infant attachment (associated with long-term developmental effects). Untreated bipolar disorder is associated with fetal growth restriction, preterm birth, adverse neurodevelopment, and may increase the risk of postpartum psychosis, worsening mood, and postpartum hospitalization. Discontinuing effective medications during pregnancy increases the risk of symptom relapse (ACOG 2023).
Patients effectively treated for schizophrenia or bipolar disorder pre-pregnancy may use the same medication during pregnancy unless contraindications exist (ACOG 2023; APA [Keepers 2020]). SGAs are better tolerated and have fewer extrapyramidal adverse effects than first-generation (typical) antipsychotics (ACOG 2023). SGAs are not considered a first-line medication for depression in pregnant patients who are treatment naive or who do not have a history of effective treatment in the past (ACOG 2023; BAP [McAllister-Williams 2017]).
Management of mental health conditions should be made as part of a shared decision-making process (ACOG 2023; BAP [McAllister-Williams 2017]). Treatment should not be withheld or discontinued based only on pregnancy status. When medications are used, the lowest effective dose of a single agent is recommended. Optimize dosing prior to changing a medication or adding additional agents whenever possible. Close monitoring for symptom improvement with a validated screening tool during pregnancy is recommended. Manage side effects as needed (ACOG 2023).
Data collection to monitor pregnancy and infant outcomes following exposure to psychiatric medications is ongoing. Encourage pregnant patients 45 years of age and younger with a history of psychiatric illness to enroll in the National Pregnancy Registry for Psychiatric Mediations (1-866-961-2388 or https://womensmentalhealth.org/research/pregnancyregistry/).
It is not known if cariprazine is present in breast milk.
According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.
Drowsiness, irritability, motor abnormalities, poor feeding, sedation, and slowed development have been reported in infants exposed to antipsychotics via breast milk. Monitor breastfed infants, especially those who are premature or of low birth weight, or when other sedative drugs are also prescribed (BAP [Barnes]; BAP [McAllister-Williams 2017]).
Frequency of Antipsychotic Monitoring for Cariprazinea,b | ||
---|---|---|
Monitoring parameter |
Frequency of monitoring |
Comments |
Adherence |
Every visit |
|
Blood chemistries (electrolytes, renal function, liver function, TSH) |
Annually |
|
CBC |
As clinically indicated |
Check frequently during the first few months of therapy in patients with preexisting low WBC or history of drug-induced leukopenia/neutropenia |
Extrapyramidal symptoms |
Every visit; 4 weeks after initiation and dose change; annually. Use a formalized rating scale at least annually or every 6 months if high riskc |
|
Fall risk |
Every visit |
|
Fasting plasma glucose/HbA1c |
4 months after initiation; annually |
Check more frequently than annually if abnormal. Follow diabetes guidelines. |
Lipid panel |
4 months after initiation; annually |
Check more frequently than annually if abnormal. Follow lipid guidelines. |
Mental status and alertness |
Every visit |
|
Metabolic syndrome history |
Annually |
Evaluate for personal and family history of obesity, diabetes, dyslipidemia, hypertension, or cardiovascular disease |
Prolactin |
Ask about symptoms at every visit until dose is stable. Check prolactin level if symptoms are reported. |
Hyperprolactinemia symptoms: Changes in menstruation, libido, gynecomastia, development of galactorrhea, and erectile and ejaculatory function |
Tardive dyskinesia |
Every visit; annually. Use a formalized rating scale at least annually or every 6 months if high riskd |
|
Vital signs (BP, orthostatics, temperature, pulse, signs of infection) |
Every visit (at least weekly during first 3 to 4 weeks of treatment); 4 weeks after dose change. |
|
Weight/Height/BMI |
8 and 12 weeks after initiation and dose change; quarterly |
Consider monitoring waist circumference at baseline and annually, especially in patients with or at risk for metabolic syndrome. Consider changing antipsychotic if BMI increases by ≥1 unit. Some experts recommend checking weight and height at every visit. |
a For all monitoring parameters, it is appropriate for check at baseline and when clinically relevant (based on symptoms or suspected ADRs) in addition to the timeline. b ADA 2004; APA [Keepers 2020]; De Hert 2011; Gugger 2011; manufacturer’s labeling. c Risk factors for extrapyramidal symptoms (EPS) include prior history of EPS, high doses of antipsychotics, young age (children and adolescents at higher risk than adults), and dopaminergic affinity of individual antipsychotic. d Risk factors for tardive dyskinesia include age >55 years; females; White or African ethnicity; presence of a mood disorder, intellectual disability, or central nervous system injury; and past or current EPS. |
Timing of serum samples: Draw trough just before next dose (Hiemke 2018).
Therapeutic reference range: 10 to 20 ng/mL (SI: 23.4 to 46.8 nmol/L) (Hiemke 2018). Note: Dosing should be based on therapeutic response as opposed to serum concentrations; however, therapeutic drug monitoring can be used to confirm adherence (APA [Keepers 2020]).
Laboratory alert level: 40 ng/mL (SI: 93.6 nmol/L) (Hiemke 2018).
Cariprazine is a second generation antipsychotic which displays partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. It exhibits high affinity for dopamine (D2 and D3) and serotonin (5-HT1A) receptors and has low affinity for serotonin 5-HT2C and alpha1A-adrenergic receptors. Cariprazine functions as an antagonist for 5-HT2B (high affinity) and 5-HT2A receptors (moderate affinity), binds to histamine H1 receptors, and has no affinity for muscarinic (cholinergic) receptors.
Onset of action: Oral:
Bipolar disorder, acute mania: Initial effects may be observed within days of treatment with continued improvements over 1 to 2 weeks (Goikolea 2013; Tohen 2000; Welten 2016).
Bipolar disorder, depressive episode: Initial effects may be observed within 1 week of treatment with continued improvements through 6 weeks (Cruz 2010).
Major depressive disorder, unipolar: Initial effects may be observed within 1 week with continued improvements over 6 to 12 weeks (Wen 2014).
Schizophrenia: Initial effects may be observed within 1 to 2 weeks of treatment with continued improvements through 4 to 6 weeks (Agid 2003; Levine 2010). Due to its long half-life and active metabolites, it may take longer for cariprazine to reach steady state at a therapeutic dose, resulting in delayed efficacy and tolerability issues compared to other antipsychotics (APA [Keepers 2020]).
Protein binding: 91% to 97%.
Metabolism: Extensively metabolized by CYP3A4 and, to a lesser extent, by CYP2D6 to active metabolites (desmethyl cariprazine [DCAR] and didesmethyl cariprazine [DDCAR]). DCAR is further metabolized into DDCAR by CYP3A4 and CYP2D6. DDCAR is then metabolized by CYP3A4 to a hydroxylated metabolite.
Half-life elimination: Cariprazine: 2 to 4 days; DCAR (active metabolite): 1 to 2 days; DDCAR (active metabolite): 1 to 3 weeks.
Time to peak, plasma: Cariprazine: 3 to 6 hours.
Excretion: Urine (21%; 1.2% as unchanged drug cariprazine).
Hepatic function impairment: Cmax and AUC for cariprazine was increased in patients with mild to moderate hepatic impairment and exposure was decreased for the active metabolites.